Indoco Remedies Limited has disclosed the incorporation of a wholly owned subsidiary through a regulatory filing submitted to both the National Stock Exchange of India Limited and Bombay Stock Exchange Limited.
The Committee of Executive Directors approved the incorporation of "Warren Lifesciences Private Limited" in their meeting held on 18th September, 2026. The meeting commenced at 05:15 p.m. (IST) and concluded at 05:45 p.m. (IST).
Subsidiary Details
- Name: Warren Lifesciences Private Limited
- Relationship: Wholly owned subsidiary of Indoco Remedies Limited
- Country of Incorporation: India
- Industry: Pharmaceutical Sector
- Business Purpose: Manufacturing, selling, and developing pharmaceutical products including active pharmaceutical ingredients, finished formulations, and key starting materials
- Status: Yet to be incorporated (date of incorporation will be intimated upon completion)
Capital Structure
- Proposed Authorized Capital: ₹1,00,000
- Paid-up Capital: ₹1,00,000
- Share Structure: 10,000 equity shares of ₹10 each
- Shareholding: 100% held by Indoco Remedies Limited
- Consideration Type: Cash consideration
- Subscription Price: Face value of ₹10 per share
Regulatory Requirements
- Name approval has been received from the Registrar of Companies, Mumbai
- Incorporation subject to approval of the Registrar of Companies/Ministry of Corporate Affairs
- Additional statutory/regulatory approvals may be required
The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.
The document was digitally signed by Ramanathan Hariharan, Company Secretary & Head Legal, on 18th September, 2026 at 17:50:30 IST.